News & Updates

Patients who receive sacubitril-valsartan after an acute myocardial infarction (MI) have a similar health status, as determined by EQ-5D visual analog scale (VAS) score, compared with those who receive ramipril, according to results of a prespecified analysis of the PARADISE-MI trial presented at HFSA 2021.

Bedside genotype testing for mutations in the CYP2C19 gene helps select a better P2Y12 inhibitor treatment strategy for patients with ST-segment elevation myocardial infarction (STEMI) and leads to better outcomes relative to conventional therapy, a recent study has found.

Use of sodium glucose co-transporter 2 inhibitors (SGLT2is) either alone or in combination with dipeptidyl peptidase 4 inhibitors (DPP4is) reduces the risk of hospitalization from heart failure (HHF), a study has shown. In contrast, thiazolidinediones alone or in combination with DPP4is increases HHF risk, but glucose-lowering can help reduce HHF.

Primary percutaneous coronary intervention (pPCI) is as good as conservative management in terms of the benefit for in-hospital mortality among ST-segment elevation myocardial infarction (STEMI) patients receiving maintenance dialysis, a study has found.

Cancer patients receiving either low-molecular-weight heparin (LMWH) or direct oral anticoagulants (DOACs) show comparable frequency of venous thromboembolism (VTE), reports a recent study.